Vis børsmeldingen
OSLO (1 DECEMBER 2020) - In 2006, NattoPharma began a research partnership with
the University of Maastricht, the Netherlands, the distinguished group that
continues to lead the exploration of K2 discovery and its role in improving
human health. This has resulted in many successes, such as partnership in the
Horizon 2020 EU ITN grants EVOluTION and INTRICARE and commercial success for
NattoPharma products improving human health.
This renewed five-year commitment will kick-off with a research project that
aims to demonstrate that vitamin K2 provides a novel solution for restoring
vascular health in patients and optimizing vascular function in a healthy
population.
“Our work with Maastricht has helped us not only create the Vitamin K2 category
but also to keep NattoPharma on the front line of research and development. The
discoveries from research continue to confirm that an adequate level of K2
guides calcium to where you need it - in your bones and teeth, and away from
your arteries and blood vessels where calcification makes them stiff,” says
NattoPharma CEO Kjetil Ramsøy.
“The work conducted in collaboration with NattoPharma will provide further
research into the role of vitamin K2 concerning calcium metabolism, impacting
various aspects of our health,” says Prof. Schurgers, Professor of Biochemistry
of Vascular Calcification and Vice-Chair of Biochemistry at the Cardiovascular
Research Institute Maastricht (CARIM), Maastricht University. “There is great
potential in learning how these mechanisms impact cardiovascular health, but
also the implications for other systems, such as bone, cartilage, brain, and
pulmonary health.”
A recent significant discovery linked a better vitamin K-status in COVID-19
patients to better outcomes. NattoPharma is excited to support this new research
project that will further explore these findings, examining the severity of
vitamin K deficiency in COVID-19 patients and investigating the role of vitamin
K2 for vascular health protection in the post-COVID-19 world.
“The first study represented an amazing finding, linking poor vitamin K status
on COVID patients with poor prognosis,” explains Prof. Schurgers, co-author of
the study. “While we do not suggest vitamin K2 is a treatment for COVID-19, we
expect this next stage of research may confirm that vitamin K2 could provide a
novel solution for optimizing vascular health. Vascular health is important as
this system needs to supply and support other organs, thereby improving outcomes
for patients with comorbidities.”
NattoPharma’s market-leading branded ingredient, MenaQ7®, has been the source
material for all clinical trials studying vitamin K2 since 2006 when
collaboration with Maastricht University began.
“We are grateful for our long and productive relationship with Maastricht and
excited for future discoveries so we can continue translating it into products
that serve the estimated 97% of the population eating a modern diet that is
deficient of this critical vitamin,” says Ramsøy.
About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the supplement industry world leader in
vitamin K2 research and development. NattoPharma is the exclusive international
supplier of MenaQ7® Vitamin K2 as MK-7, the best-documented vitamin K2 as
menaquinone-7 (MK-7) with guaranteed actives and stability, clinical
substantiation, and international patents granted and pending; and now MenaQ7®
Full Spectrum, which delivers menaquinones 6, 7, and 9. The company has a multi
-year research and development program to substantiate and discover the health
benefits of Vitamin K2 for applications in the marketplace for functional food
and dietary supplements, in addition to exclusive access to the research efforts
of its pharmaceutical arm, Kaydence Pharma AS (est. 2017), outside of the
pharmaceutical domain. With a global presence, the company established its North
American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D
Ltd. in Cyprus. For more information, visit www.nattopharma.com or
www.menaq7.com.
For more information, please contact:
Kate Quackenbush, Director of Communications
Telephone : +1 609-643-0749 x 220
Email : kate.quackenbush@nattopharma.com
Kilde
